-
1
-
-
34547122001
-
The 2007 WHO classification of tumours of the central nervous system
-
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
-
(2007)
Acta Neuropathol.
, vol.114
, pp. 97-109
-
-
Louis, D.N.1
Ohgaki, H.2
Wiestler, O.D.3
-
2
-
-
34249285571
-
Anaplastic astrocytoma in adults
-
Stupp R, Reni M, Gatta G, Mazza E, Vecht C. Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol. 2007;63:72-80.
-
(2007)
Crit Rev Oncol Hematol
, vol.63
, pp. 72-80
-
-
Stupp, R.1
Reni, M.2
Gatta, G.3
Mazza, E.4
Vecht, C.5
-
3
-
-
37449003812
-
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
-
Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9:29-38.
-
(2008)
Lancet Oncol
, vol.9
, pp. 29-38
-
-
Gorlia, T.1
Van Den Bent, M.J.2
Hegi, M.E.3
-
5
-
-
0032767387
-
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials
-
Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572-2578.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2572-2578
-
-
Wong, E.T.1
Hess, K.R.2
Gleason, M.J.3
-
6
-
-
34447285771
-
Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase i and II clinical trials
-
Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007;25:2601-2606.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2601-2606
-
-
Carson, K.A.1
Grossman, S.A.2
Fisher, J.D.3
Shaw, E.G.4
-
7
-
-
38749146312
-
Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide
-
Nagane M, Kobayashi K, Ohnishi A, Shimizu S, Shiokawa Y. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol. 2007;37:897-906.
-
(2007)
Jpn J Clin Oncol
, vol.37
, pp. 897-906
-
-
Nagane, M.1
Kobayashi, K.2
Ohnishi, A.3
Shimizu, S.4
Shiokawa, Y.5
-
8
-
-
32944469010
-
Changing paradigms-an update on the multidisciplinary management of malignant glioma
-
European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups National Cancer Institute of Canada Clinical Trials Group.
-
Stupp R, Hegi ME, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11:165-180.
-
(2006)
Oncologist
, vol.11
, pp. 165-180
-
-
Stupp, R.1
Hegi, M.E.2
Van Den Bent, M.J.3
-
9
-
-
0043236350
-
Summary version of the Standards Options and Recommendations for the management of adult patients with intracranial glioma 2002)
-
FNCLCC; Neuro-oncology Group of the Fédé ration Nationale des Centres de Lutte Contre le Cancer; Association of French-speaking Neuro-oncologists
-
Frappaz D, Chinot O, Bataillard A, et al. FNCLCC; Neuro-oncology Group of the Fédé ration Nationale des Centres de Lutte Contre le Cancer; Association of French-speaking Neuro-oncologists. Summary version of the Standards, Options and Recommendations for the management of adult patients with intracranial glioma (2002). Br J Cancer. 2003;89(Suppl.):73-83.
-
(2003)
Br J Cancer.
, vol.89
, Issue.SUPPL.
, pp. 73-83
-
-
Frappaz, D.1
Chinot, O.2
Bataillard, A.3
-
10
-
-
70350461699
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
-
Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4733-4740
-
-
Friedman, H.S.1
Prados, M.D.2
Wen, P.Y.3
-
11
-
-
78449274656
-
A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
-
Raizer JJ, Grimm S, Chamberlain MC, et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. 2010;116: 5297-5305.
-
(2010)
Cancer.
, vol.116
, pp. 5297-5305
-
-
Raizer, J.J.1
Grimm, S.2
Chamberlain, M.C.3
-
12
-
-
33947191055
-
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
-
Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253-1259.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1253-1259
-
-
Vredenburgh, J.J.1
Desjardins, A.2
Je, H.Ii.3
-
13
-
-
67649410669
-
Bevacizumab and irinotecan for recurrent oligodendroglial tumors
-
Taillibert S, Vincent LA, Granger B, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology. 2009;72:1601-1606.
-
(2009)
Neurology
, vol.72
, pp. 1601-1606
-
-
Taillibert, S.1
Vincent, L.A.2
Granger, B.3
-
14
-
-
75649124562
-
Bevacizumab and irinotecan for recurrent oligodendroglial tumors
-
Chamberlain MC. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology. 2010;74:181.
-
(2010)
Neurology.
, vol.74
, pp. 181
-
-
Chamberlain, M.C.1
-
15
-
-
80755159087
-
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma
-
Kreisl TN, Zhang W, Odia Y, et al. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol. 2011;13:1143-1150.
-
(2011)
Neuro Oncol.
, vol.13
, pp. 1143-1150
-
-
Kreisl, T.N.1
Zhang, W.2
Odia, Y.3
-
16
-
-
13744253539
-
Imaging angiogenesis: Applications and potential for drug development
-
Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst. 2005;97:172-187.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 172-187
-
-
Miller, J.C.1
Pien, H.H.2
Sahani, D.3
Sorensen, A.G.4
Thrall, J.H.5
-
17
-
-
0028129321
-
Multimodality management of recurrent adult malignant gliomas: Results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery
-
Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery. 1994;35: 378-388.
-
(1994)
Neurosurgery
, vol.35
, pp. 378-388
-
-
Rostomily, R.C.1
Spence, A.M.2
Duong, D.3
McCormick, K.4
Bland, M.5
Berger, M.S.6
-
18
-
-
0031016159
-
18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma
-
Barker FG, 2nd, Chang SM, Valk PE, Pounds TR, Prados MD. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer. 1997;79:115-126.
-
(1997)
Cancer
, vol.79
, pp. 115-126
-
-
Fg, B.Ii.1
Chang, S.M.2
Valk, P.E.3
Pounds, T.R.4
Prados, M.D.5
-
19
-
-
36048955738
-
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study
-
Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25: 4714-4721.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4714-4721
-
-
Chen, W.1
Delaloye, S.2
Silverman, D.H.3
-
21
-
-
79958148395
-
O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma
-
Hutterer M, Nowosielski M, Putzer D, et al. O-(2-18F-fluoroethyl)-L- tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011;52:856-864.
-
(2011)
J Nucl Med.
, vol.52
, pp. 856-864
-
-
Hutterer, M.1
Nowosielski, M.2
Putzer, D.3
-
23
-
-
12444279265
-
On the origin of cancer cells
-
Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
-
(1956)
Science
, vol.123
, pp. 309-314
-
-
Warburg, O.1
-
24
-
-
0034531084
-
FDG-PET as a prognostic factor in high-grade astrocytoma
-
De Witte O, Lefranc F, Levivier M, Salmon I, Brotchi J, Goldman S. FDG-PET as a prognostic factor in high-grade astrocytoma. J Neurooncol. 2000;49:157-163.
-
(2000)
J Neurooncol
, vol.49
, pp. 157-163
-
-
De Witte, O.1
Lefranc, F.2
Levivier, M.3
Salmon, I.4
Brotchi, J.5
Goldman, S.6
-
25
-
-
0020377044
-
Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography
-
Di Chiro G, DeLaPaz RL, Brooks RA, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323-1329.
-
(1982)
Neurology
, vol.32
, pp. 1323-1329
-
-
Di Chiro, G.1
Delapaz, R.L.2
Brooks, R.A.3
-
26
-
-
84864329014
-
Independant prognostic value of pre-treatment 18-FDG-PET in high grade gliomas
-
[published online ahead of print December 15 2011]. doi:10.1007/s11060- 011-0771-6
-
Colavolpe C, Metellus P, Mancini J, et al. Independant prognostic value of pre-treatment 18-FDG-PET in high grade gliomas. J Neurooncol [published online ahead of print December 15, 2011]. doi:10.1007/s11060-011-0771-6.
-
J Neurooncol
-
-
Colavolpe, C.1
Metellus, P.2
Mancini, J.3
-
27
-
-
0021798805
-
Prediction of survival in glioma patients by means of positron emission tomography
-
Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg. 1985;62:816-822.
-
(1985)
J Neurosurg
, vol.62
, pp. 816-822
-
-
Patronas, N.J.1
Di Chiro, G.2
Kufta, C.3
-
28
-
-
0141794250
-
Prediction of pathology and survival by FDG PET in gliomas
-
Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol. 2003;64:227-237.
-
(2003)
J Neurooncol
, vol.64
, pp. 227-237
-
-
Padma, M.V.1
Said, S.2
Jacobs, M.3
-
29
-
-
0031968208
-
Preoperative evaluation of 54 gliomas by PET with fluorine-18- fluorodeoxyglucose and/or carbon-11-methionine
-
Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778-785.
-
(1998)
J Nucl Med
, vol.39
, pp. 778-785
-
-
Kaschten, B.1
Stevenaert, A.2
Sadzot, B.3
-
30
-
-
0027313527
-
FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma
-
Hö lzer T, Herholz K, Jeske J, Heiss WD. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr. 1993;17:681-687.
-
(1993)
J Comput Assist Tomogr
, vol.17
, pp. 681-687
-
-
Hölzer, T.1
Herholz, K.2
Jeske, J.3
Heiss, W.D.4
-
31
-
-
50649095167
-
FDG-PET to predict different patterns of progression in multicentric glioblastoma: A case report
-
Colavolpe C, Guedj E, Metellus P, et al. FDG-PET to predict different patterns of progression in multicentric glioblastoma: a case report. J Neurooncol. 2008;90:47-51.
-
(2008)
J Neurooncol
, vol.90
, pp. 47-51
-
-
Colavolpe, C.1
Guedj, E.2
Metellus, P.3
-
32
-
-
0036554829
-
2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: Correlation with outcome
-
Spence AM, Muzi M, Graham MM, et al. 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome. Clin Cancer Res. 2002;8:971-979.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 971-979
-
-
Spence, A.M.1
Muzi, M.2
Graham, M.M.3
-
33
-
-
33645969631
-
Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies
-
Cher LM, Murone C, Lawrentschuk N, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47:410-418.
-
(2006)
J Nucl Med
, vol.47
, pp. 410-418
-
-
Cher, L.M.1
Murone, C.2
Lawrentschuk, N.3
-
34
-
-
33645991547
-
Microvessel density: Correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas
-
Guo J, Higashi K, Ueda Y, et al. Microvessel density: correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J Nucl Med. 2006;47:419-425.
-
(2006)
J Nucl Med
, vol.47
, pp. 419-425
-
-
Guo, J.1
Higashi, K.2
Ueda, Y.3
-
35
-
-
33750351328
-
European Association of Nuclear Medicine (EANM). EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues
-
Vander Borght T, Asenbaum S, Bartenstein P, et al. European Association of Nuclear Medicine (EANM). EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging. 2006;33:1374-1380.
-
(2006)
Eur J Nucl Med Mol Imaging
, vol.33
, pp. 1374-1380
-
-
Vander Borght, T.1
Asenbaum, S.2
Bartenstein, P.3
-
36
-
-
77951625266
-
Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group
-
Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-72.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.11
, pp. 1963-72
-
-
Wen, P.Y.1
MacDonald, D.R.2
Reardon, D.A.3
-
37
-
-
0022885139
-
Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution
-
Hamacher K, Coenen HH, Stö cklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
-
(1986)
J Nucl Med
, vol.27
, pp. 235-238
-
-
Hamacher, K.1
Coenen, H.H.2
Stöcklin, G.3
-
39
-
-
33744540372
-
Optimization of semiquantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas
-
Borbé ly K, Nyá ry I, Tó th M, Ericson K, Gulyá s B. Optimization of semiquantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci. 2006;246:85-94.
-
(2006)
J Neurol Sci
, vol.246
, pp. 85-94
-
-
Borbély, K.1
Nyáry, I.2
Tóth, M.3
Ericson, K.4
Gulyás, B.5
-
40
-
-
3042730538
-
High and low grade oligodendrogliomas (ODG): Correlation of amino-acid and glucose uptakes using PET and histological classifications
-
Giammarile F, Cinotti LE, Jouvet A, et al. High and low grade oligodendrogliomas (ODG): correlation of amino-acid and glucose uptakes using PET and histological classifications. J Neurooncol. 2004;68:263-274.
-
(2004)
J Neurooncol
, vol.68
, pp. 263-274
-
-
Giammarile, F.1
Cinotti, L.E.2
Jouvet, A.3
-
41
-
-
0035111816
-
Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses
-
Meyer PT, Schreckenberger M, Spetzger U, et al. Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses. Eur J Nucl Med. 2001;28:165-174.
-
(2001)
Eur J Nucl Med
, vol.28
, pp. 165-174
-
-
Meyer, P.T.1
Schreckenberger, M.2
Spetzger, U.3
-
42
-
-
0025075721
-
Over-expression of facilitative glucose transporter genes in human cancer
-
Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 1990;170:223-230.
-
(1990)
Biochem Biophys Res Commun
, vol.170
, pp. 223-230
-
-
Yamamoto, T.1
Seino, Y.2
Fukumoto, H.3
-
44
-
-
0001644841
-
Oxygen consumption and anaerobic glycolysis of human malignant and normal tissue
-
Macbeth RAL, Bekesi JG. Oxygen Consumption and Anaerobic Glycolysis of Human Malignant and Normal Tissue. Cancer Res. 1962;22:244-248.
-
(1962)
Cancer Res
, vol.22
, pp. 244-248
-
-
MacBeth, R.A.L.1
Bekesi, J.G.2
-
45
-
-
12444257678
-
Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: Sensitivity, inter-observer variability and prognostic value
-
Van Laere K, Ceyssens S, Van Calenbergh F, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2005;32:39-51.
-
(2005)
Eur J Nucl Med Mol Imaging
, vol.32
, pp. 39-51
-
-
Van Laere, K.1
Ceyssens, S.2
Van Calenbergh, F.3
-
46
-
-
23044460494
-
Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG
-
Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005;46:945-952.
-
(2005)
J Nucl Med
, vol.46
, pp. 945-952
-
-
Chen, W.1
Cloughesy, T.2
Kamdar, N.3
-
47
-
-
0027325729
-
Glucose consumption in recurrent gliomas
-
Ishikawa M, Kikuchi H, Miyatake S, Oda Y, Yonekura Y, Nishizawa S. Glucose consumption in recurrent gliomas. Neurosurgery. 1993;33: 28-33.
-
(1993)
Neurosurgery
, vol.33
, pp. 28-33
-
-
Ishikawa, M.1
Kikuchi, H.2
Miyatake, S.3
Oda, Y.4
Yonekura, Y.5
Nishizawa, S.6
-
48
-
-
33748327010
-
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy
-
Charnley N, West CM, Barnett CM, et al. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66: 331-338.
-
(2006)
Int J Radiat Oncol Biol Phys
, vol.66
, pp. 331-338
-
-
Charnley, N.1
West, C.M.2
Barnett, C.M.3
-
49
-
-
59949083263
-
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
-
Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27: 740-745.
-
(2009)
J Clin Oncol
, vol.27
, pp. 740-745
-
-
Kreisl, T.N.1
Kim, L.2
Moore, K.3
-
50
-
-
38549145873
-
18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy
-
Funaioli C, Pinto C, Di Fabio F, et al. 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy. Tumori. 2007;93:611-615.
-
(2007)
Tumori
, vol.93
, pp. 611-615
-
-
Funaioli, C.1
Pinto, C.2
Di Fabio, F.3
-
51
-
-
33646675851
-
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
-
Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66:1258-1260.
-
(2006)
Neurology
, vol.66
, pp. 1258-1260
-
-
Pope, W.B.1
Lai, A.2
Nghiemphu, P.3
Mischel, P.4
Cloughesy, T.F.5
|